Library · Metabolic & weight · Progressive familial intrahepatic cholestasis
Odevixibat
Bylvay
An IBAT-inhibiting drug approved by the FDA in 2021 for progressive familial intrahepatic cholestasis, giving the first non-surgical option to interrupt bile-acid recycling and reduce itching and serum bile-acid levels.
Research score 80/100. Reference only, not a dose.
- Pruritus Relief
- Bile Acid Reduction
- US status
- Prescription Only
- Approval
- FDA Approved (2021)
- Evidence
- Phase 3 trial: 33% bile acid response vs 0% placebo. Significant pruritus reduction
- Research score
- 80 / 100
- Indication
- Progressive familial intrahepatic cholestasis (PFIC)
- Origin
- United States
- Source category
- Gastrointestinal & Hepatic
- Status group
- Approved / prescription
Mechanism
Blocks the ileal bile acid transporter, interrupting enterohepatic circulation and boosting fecal bile-acid loss.
Safety file
Generally well tolerated; diarrhea is the most frequent side effect.
- Diarrhea or frequent bowel movements (31% vs 10% placebo)
- Fever (29%)